They're the winners of the second annual Johnson & Johnson WiSTEM2D Scholars Award, thanks to such amazing innovations as tattoos that can monitor changes in your metabolism. Meet them and their groundbreaking work.
Article
A better, smarter 3-D printer. A gel that could speed up wound healing—and minimize scarring. Tattoos that could monitor your metabolism.
These are just a sampling of the big ideas the winners of Johnson & Johnson’s second annual WiSTEM2D Scholars Award Program are hoping to one day bring to market.
LEVERKUSEN, Germany, April 18, 2019 /3BL Media/ – Bayer’s Board of Management has appointed Dr. Monika Lessl as Bayer Foundations’ executive committee member to lead both the Bayer Science Foundation and the Bayer Cares Foundation. This role will be integrated into her current leadership of Bayer’s Corporate Innovation and R&D function.
Millions of people in developing countries have no access to medicines. In some cases they cannot afford them, while in others there simply are no markets and no functioning healthcare system. We are working to provide help in a number of ways. With our contraception access programs, for example, we aim to make self-determined family planning available to women in order to reduce maternal and infant mortality.
More than 220 cattle professionals engage over key topics of parasite control, bovine respiratory disease, reproduction, digital innovation and well-being at the 2nd Bayer International Beef Symposium
Press Release
MONHEIM, Germany & RIBEIRÃO PRETO, Brazil, April 10, 2019 /3BL Media/ –Bayer brought together global thought leaders in beef cattle health and management to share the latest in research and innovation at its 2nd International Beef Symposium in Ribeirão Preto, Brazil from 31st March to 2nd April.
Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5
Press Release
Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5
Kids like Ethan are why Aflac has been a corporate ally for the childhood cancer community for 24 years. Through innovative research and helping provide peace of mind to patients and their families, Aflac’s commitment to helping find a cure for pediatric cancer holds strong. Every child deserves a lifetime.
Novo Nordisk has published its integrated 2018 Annual Report detailing the company’s year-end performance. The report highlights the company’s progression towards long-term targets taking an integrated approach that accounts for financial, social and environmental performance. This is the company’s 15th integrated report.
Ebola, and HIV before it, shows what can be accomplished once a disease is catapulted to the top of the global agenda.
Dr. Paul Stoffels, Johnson & Johnson's chief scientific officer, says tuberculosis is a far deadlier disease, but has not received this sort of attention and focus from the global community.
An outdated and inadequate toolbox is largely to blame for the unacceptably high toll of TB.
Article
Ebola, and HIV before it, shows what can be accomplished once a disease is catapulted to the top of the global agenda.
Dr. Paul Stoffels, Johnson & Johnson's chief scientific officer, says tuberculosis is a far deadlier disease, but has not received this sort of attention and focus from the global community.
An outdated and inadequate toolbox is largely to blame for the unacceptably high toll of TB.
In the lead-up to the recent International AIDS Society Conference on HIV Science in the Netherlands, we sat down with Hanneke Schuitemaker, who's hard at work on the holy grail of HIV research: a preventive treatment.
Article
By Sheila Weller
In 1992, as a young HIV/AIDS researcher in her native Netherlands, Hanneke Schuitemaker, Ph.D., now Vice President, Global Head of Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines & Prevention B.V., was devoted to learning as much as she could about the disease—and saw her role as that of a researcher, rather than someone who closely interacted with people who were living with HIV.
At Astellas, we are dedicated to supporting and improving the lives of those impacted by cancer. One of the ways we provide this support is by working with patient advocacy organizations, such as The Leukemia and Lymphoma Society (LLS) – the world's largest voluntary health agency dedicated to blood cancers, including leukemia, lymphoma, Hodgkin's disease and myeloma.
